PHATHOM PHARMACEUTICALS, INC. Research and Development Expense
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Research and Development Expense of $7.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $7.81M, a 13.92% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $7.77M, a 15.39% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $7.49M, a 12.70% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $7.03M, a 19.16% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $32.78M, a 3.82% decline from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $34.08M, a 31.70% decline from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $49.90M, a 30.15% decline from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $71.44M, a 1.24% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.81M 10-Q · filed 2026-07-30 | $15.59M 10-Q · filed 2026-07-30 | $23.08M derived: sum of 3 quarters · filed 2026-07-30 | $30.10M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $7.77M 10-Q · filed 2026-04-30 | $15.26M derived: sum of 2 quarters · filed 2026-04-30 | $22.29M derived: sum of 3 quarters · filed 2026-04-30 | $31.37M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $7.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $14.52M derived: sum of 2 quarters · filed 2026-02-26 | $23.60M derived: sum of 3 quarters · filed 2026-07-30 | $32.78M 10-K · filed 2026-02-26 |
| 2025-09-30 | $7.03M 10-Q · filed 2025-10-30 | $16.10M derived: sum of 2 quarters · filed 2026-07-30 | $25.29M 10-Q · filed 2025-10-30 | $33.87M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $9.08M 10-Q · filed 2026-07-30 | $18.26M 10-Q · filed 2026-07-30 | $26.84M derived: sum of 3 quarters · filed 2026-07-30 | $35.54M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $9.18M 10-Q · filed 2026-04-30 | $17.77M derived: sum of 2 quarters · filed 2026-04-30 | $26.46M derived: sum of 3 quarters · filed 2026-04-30 | $33.84M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $8.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $17.28M derived: sum of 2 quarters · filed 2026-02-26 | $24.65M derived: sum of 3 quarters · filed 2026-02-26 | $34.08M 10-K · filed 2026-02-26 |
| 2024-09-30 | $8.69M 10-Q · filed 2025-10-30 | $16.07M derived: sum of 2 quarters · filed 2025-10-30 | $25.50M 10-Q · filed 2025-10-30 | $38.89M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $7.38M 10-Q · filed 2025-08-07 | $16.81M 10-Q · filed 2025-08-07 | $30.20M derived: sum of 3 quarters · filed 2025-08-07 | $42.46M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $9.43M 10-Q · filed 2025-05-01 | $22.82M derived: sum of 2 quarters · filed 2025-05-01 | $35.09M derived: sum of 3 quarters · filed 2025-05-01 | $47.85M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $13.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $25.66M derived: sum of 2 quarters · filed 2025-03-06 | $38.42M derived: sum of 3 quarters · filed 2025-03-06 | $49.90M 10-K · filed 2025-03-06 |
| 2023-09-30 | $12.26M 10-Q · filed 2024-11-07 | $25.03M derived: sum of 2 quarters · filed 2024-11-07 | $36.51M 10-Q · filed 2024-11-07 | $52.45M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $12.76M 10-Q · filed 2024-08-08 | $24.24M 10-Q · filed 2024-08-08 | $40.19M derived: sum of 3 quarters · filed 2024-08-08 | $59.21M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $11.48M 10-Q/A · filed 2024-06-14 | $27.43M derived: sum of 2 quarters · filed 2024-06-14 | $46.45M derived: sum of 3 quarters · filed 2024-06-14 | $65.26M derived: sum of 4 quarters · filed 2024-06-14 |
| 2022-12-31 | $15.95M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | $34.97M derived: sum of 2 quarters · filed 2024-06-14 | $53.78M derived: sum of 3 quarters · filed 2024-06-14 | $71.44M 10-K/A · filed 2024-06-14 |
| 2022-09-30 | $19.02M 10-Q · filed 2023-11-09 | $37.84M derived: sum of 2 quarters · filed 2023-11-09 | $55.49M 10-Q · filed 2023-11-09 | $69.05M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $18.82M 10-Q · filed 2023-08-10 | $36.48M 10-Q · filed 2023-08-10 | $50.03M derived: sum of 3 quarters · filed 2023-08-10 | $66.64M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $17.66M 10-Q · filed 2023-05-10 | $31.21M derived: sum of 2 quarters · filed 2023-05-10 | $47.82M derived: sum of 3 quarters · filed 2023-05-10 | $69.42M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $13.55M derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | $30.16M derived: sum of 2 quarters · filed 2023-02-28 | $51.76M derived: sum of 3 quarters · filed 2023-02-28 | $72.34M 10-K · filed 2023-02-28 |
| 2021-09-30 | $16.61M 10-Q/A · filed 2022-11-09 | $38.20M derived: sum of 2 quarters · filed 2022-11-09 | $58.79M 10-Q/A · filed 2022-11-09 | $100.44M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $21.60M 10-Q · filed 2022-08-02 | $42.18M 10-Q · filed 2022-08-02 | $83.83M derived: sum of 3 quarters · filed 2022-08-02 | $109.60M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $20.58M 10-Q · filed 2022-05-10 | $62.23M derived: sum of 2 quarters · filed 2022-05-10 | $88.00M derived: sum of 3 quarters · filed 2022-05-10 | $102.86M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $41.65M 10-K · filed 2021-03-30 | $67.42M derived: sum of 2 quarters · filed 2021-11-08 | $82.28M derived: sum of 3 quarters · filed 2021-11-08 | $98.15M 10-K · filed 2022-03-01 |
| 2020-09-30 | $25.77M 10-Q · filed 2021-11-08 | $40.63M derived: sum of 2 quarters · filed 2021-11-08 | $56.49M 10-Q · filed 2021-11-08 | $69.20M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $14.86M 10-Q · filed 2021-08-10 | $30.72M 10-Q · filed 2021-08-10 | $43.43M derived: sum of 3 quarters · filed 2021-08-10 | $47.90M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $15.87M 10-Q · filed 2021-05-11 | $28.57M derived: sum of 2 quarters · filed 2021-05-11 | $33.04M derived: sum of 3 quarters · filed 2021-05-11 | $35.81M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $12.70M 10-K · filed 2021-03-30 | $17.17M derived: sum of 2 quarters · filed 2021-03-30 | $19.95M derived: sum of 3 quarters · filed 2021-03-30 | $20.37M 10-K · filed 2021-03-30 |
| 2019-09-30 | $4.47M 10-K · filed 2021-03-30 | $7.24M derived: sum of 2 quarters · filed 2021-03-30 | $7.67M 10-Q · filed 2020-11-10 | $7.68M derived: sum of 4 quarters · filed 2021-03-30 |
| 2019-06-30 | $2.77M 10-K · filed 2021-03-30 | $3.20M 10-Q · filed 2020-08-06 | $3.21M derived: sum of 3 quarters · filed 2021-03-30 | $3.22M derived: sum of 4 quarters · filed 2021-03-30 |
| 2019-03-31 | $429.00K 10-K · filed 2021-03-30 | $443.00K derived: sum of 2 quarters · filed 2021-03-30 | $449.00K derived: sum of 3 quarters · filed 2021-03-30 | |
| 2018-12-31 | $14.00K 10-K · filed 2020-03-19 | $20.00K derived: sum of 2 quarters · filed 2020-03-19 | $20.00K 10-K · filed 2020-03-19 | |
| 2018-09-30 | $6.00K 10-K · filed 2020-03-19 | $6.00K 10-Q · filed 2019-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |